Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.54 |
| ▸ | SYK | P43405 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12400317 | 0.89 | JAK3 (0.51) | JAK3SYKCYP2D6CYP2C9MAPK1 | |
| SCHEMBL2275295 | 0.85 | JAK3 (0.57) | JAK3SYKCYP2D6CYP2C9MAPK1 | |
| SCHEMBL2277585 | 0.84 | JAK3 (0.60) | JAK3SYKCYP2D6CYP2C9MAPK1 | |
| SCHEMBL2278622 | 0.84 | JAK3 (0.56) | JAK3SYKCYP2D6CYP2C9MAPK1 | |
| SCHEMBL2343901 | 0.83 | JAK3 (0.59) | JAK3SYKCYP2D6CYP2C9MAPK1 | |
| SCHEMBL27801753 | 0.83 | JAK3 (0.51) | JAK3SYKCYP2D6CYP2C9MAPK1 | |
| SCHEMBL2272897 | 0.83 | JAK3 (0.57) | JAK3SYKCYP2D6CYP2C9MAPK1 | |
| SCHEMBL1634076 | 0.83 | JAK3 (0.58) | JAK3SYKCYP2D6CYP2C9MAPK1 | |
| SCHEMBL2276701 | 0.83 | JAK3 (0.58) | JAK3SYKCYP2D6CYP2C9MAPK1 | |
| SCHEMBL2278115 | 0.83 | JAK3 (0.58) | JAK3SYKCYP2D6CYP2C9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | JAK3 7/4885SYK 1/4885CYP2D6 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.